KPRX
$2.10
Pre-MarketAs of Mar 17, 8:00 PM UTC
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases.
Recent News
Vicarious Surgical names Stephen From as next CEO
From, who joins the surgical robot developer from Aruna Bio, will take the reins from co-founder Adam Sachs on Aug. 7.
Kiora Pharmaceuticals (KPRX) Upgraded to Strong Buy: Here's What You Should Know
Kiora Pharmaceuticals (KPRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Top Midday Gainers
ReShape Lifesciences (RSLS) said Tuesday that its Quality Management System and entire commercial po